Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
Oragenics, Inc. logo

AMEX · OGEN

Oragenics, Inc.

Healthcare · Biotechnology

$0.37

Down-$0.00 (-1.02%)

Updated Nov 3, 2026, 6:08 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
3.88M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.35 – $1.29
Volume
47.83K
Avg. volume
130.21K

Price performance · OGEN

OGEN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

OGEN closed at $0.37 after 21 trading sessions, down 23.84% for the selected period.

Last close
$0.37
Period change
-23.84%
Period low
$0.37
Period high
$0.50
Daily close
View OHLC price history
OGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$0.4194$0.4194$0.37$0.370247.83K
Oct 30, 2026$0.3727$0.3855$0.3711$0.3749.21K
Oct 29, 2026$0.3764$0.3814$0.372$0.37426.36K
Oct 28, 2026$0.381$0.3982$0.37$0.3813.8K
Oct 27, 2026$0.397$0.397$0.3508$0.36662.81K
Oct 26, 2026$0.419$0.419$0.3979$0.398518.49K
Oct 23, 2026$0.4052$0.4171$0.404$0.41719.46K
Oct 22, 2026$0.4072$0.4129$0.40$0.405320.42K
Oct 21, 2026$0.4372$0.4372$0.4127$0.41285.36K
Oct 20, 2026$0.436$0.447$0.4056$0.43414.82K
Oct 19, 2026$0.4358$0.4468$0.418$0.42235.99K
Oct 16, 2026$0.4538$0.4538$0.43$0.434932.73K
Oct 15, 2026$0.4349$0.4599$0.43$0.43611.62K
Oct 14, 2026$0.4519$0.4519$0.43$0.43716.93K
Oct 13, 2026$0.4522$0.4535$0.44$0.446916.63K
Oct 12, 2026$0.4561$0.4625$0.4456$0.447617.2K
Oct 9, 2026$0.4714$0.4839$0.45$0.45628.22K
Oct 8, 2026$0.495$0.50$0.463$0.46345.86K
Oct 7, 2026$0.4999$0.50$0.4895$0.499911.69K
Oct 6, 2026$0.4858$0.4874$0.4751$0.48512.3K
Oct 5, 2026$0.478$0.5049$0.478$0.486142.47K

Latest OGEN news

The latest Smart Investors Daily articles mentioning OGEN.

Stock researchCompany · Overview

OGEN research

Overview

Company profile and research snapshot.

Company profile

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
OGEN recent ratings
DateFirmRatingTarget
Jun 3, 2021Goldman SachsNeutral—
Apr 16, 2020H.C. WainwrightNeutral—
Nov 15, 2019UBSNeutral—
Apr 26, 2019H.C. WainwrightBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026Presentation is expected to address development and clinical translation of ONP-002, including the intranasal delivery platform, Phase IIa trial design, and anticipated path to U.S. clinical develo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By